This exploration compound was first described by Hoffman-La Roche in 2009. It’s considered one of various benzodiazepines within the imidazobenzodiazepine subgroup considered to provide nootropic Advantages. It’s unclear why this drug wasn’t investigated even more, but you'll find experiences this compound is detected on designer and street-stage drug marketplaces [112]. https://mannersv470ejm8.blogitright.com/profile